Magnus Medical develops non-invasive neuromodulation systems designed to treat severe depression through personalized brain network targeting. The company’s platform, SAINT®, uses image-guided stimulation to deliver accelerated therapeutic protocols. Its approach focuses on tailoring treatment to individual brain connectivity patterns rather than relying on standardized stimulation sites. Magnus Medical positions its technology within regulated clinical treatment pathways.

The technology integrates brain imaging with transcranial magnetic stimulation to identify and target patient-specific neural networks associated with depression. Stimulation is delivered in an accelerated protocol, concentrating treatment into a shorter time frame compared to conventional approaches. By aligning stimulation with individualized network architecture, the system aims to improve consistency and therapeutic response. The platform emphasizes precision, repeatability, and clinical rigor.

Magnus Medical targets patients with treatment-resistant or severe depression who require alternatives to medication and standard therapies. The SAINT® system is intended for use in specialized clinical settings under professional supervision. Its focus reflects broader movement toward personalized, network-based neuromodulation strategies in psychiatric care.